Dr Samantha Walker: key facts
- Kind of voice
- Sector leader
- Role
- Director of Research & Innovation at Asthma + Lung UK
- Quoted on
- Respiratory (asthma/COPD)
- Tracked press citations
- 3
- Most recently quoted
- 30 Sept 2026
“This study is a promising sign that tezepelumab injections support certain people with severe asthma to reduce or stop taking steroid tablets, which can have serious unwanted health consequences.”
What Dr Samantha Walker has said
“This is an incredibly encouraging development for the future of asthma care that could transform the lives of people with severe asthma.”
director of research and innovation at Asthma + Lung UK · Respiratory (asthma/COPD) · 10 Sept 2026 · Severe asthma can be controlled by a monthly injection, trial finds ↗
“This study is a promising sign that tezepelumab injections support certain people with severe asthma to reduce or stop taking steroid tablets, which can have serious unwanted health consequences.”
director of research and innovation at Asthma + Lung UK · Respiratory (asthma/COPD) · 10 Sept 2026 · Half of severe asthma patients started on tezepelumab able to stop oral steroids ↗
Where Dr Samantha Walker has been quoted
- Monthly injection helps severe asthma patients safely stop or reduce daily steroidskcl.ac.uk · 30 Sept 2026
- Severe asthma can be controlled by a monthly injection, trial findstheguardian.com · 10 Sept 2026
- Half of severe asthma patients started on tezepelumab able to stop oral steroidspulsetoday.co.uk · 10 Sept 2026
Related media coverage
Recent UK press coverage of their topics — not necessarily citing them directly.
Chief executives, directors and spokespeople of trade bodies, representative associations and charities speaking for the sector. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 5 Oct 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.